KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables: 2013-2025

Historic Receivables for Xenon Pharmaceuticals (XENE) over the last 10 years, with Mar 2025 value amounting to $8.6 million.

  • Xenon Pharmaceuticals' Receivables rose 938.30% to $8.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $13.4 million, marking a year-over-year increase of 188.63%. This contributed to the annual value of $2.9 million for FY2024, which is 236.16% up from last year.
  • Xenon Pharmaceuticals' Receivables amounted to $8.6 million in Q1 2025, which was up 194.38% from $2.9 million recorded in Q4 2024.
  • Xenon Pharmaceuticals' 5-year Receivables high stood at $8.6 million for Q1 2025, and its period low was $805,000 during Q3 2023.
  • Moreover, its 3-year median value for Receivables was $938,000 (2024), whereas its average is $2.2 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Receivables plummeted by 67.57% in 2023 and then spiked by 938.30% in 2025.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Receivables stood at $2.8 million in 2021, then plummeted by 64.34% to $986,000 in 2022, then declined by 11.36% to $874,000 in 2023, then spiked by 236.16% to $2.9 million in 2024, then soared by 938.30% to $8.6 million in 2025.
  • Its Receivables was $8.6 million in Q1 2025, compared to $2.9 million in Q4 2024 and $938,000 in Q3 2024.